Fentanyl is indicated for the management of severe pain in patients who require continuous opioid analgesia (mechanism of action: strong agonist of specific opioid receptors).

Indicated for chronic and intractable pain, Amarin developed a Fentanyl TDS using its drug-in-adhesive technology. Fentanyl TDS is currently commercialized in Germany, France, Hungary and Argentine under different brand names (Fentadolon®, Fentanyl Biogaran®, Dolforin®, Talnur®, etc) in four strengths. Presently, Fentanyl TDS is finalizing the Mutual Recognition Procedure in Europe and is in registration phase in Latinamerica.

Europe (1503743), Mexico (245834) and India (216861). Two International Patent Applications were filed 2003 (PCT/BG03/002118). In 2004 a re-validation was submitted in USA (US 20050208116).

Amarin is willing to consider a range of partnership options for this TDS.